The Mood Disorders Program is actively seeking participants for the following three studies.
- Depression Study: The Mood Disorders Program is participating in a multicenter study evaluating the use of potential new medication for major depression. All patients will receive a standard antidepressant and, if needed, the new medication will be added to the antidepressant. Eligible patients will be provided evaluation, laboratory tests, medications, and follow up at no cost. Participants will also be compensated at each visit for their time and for travel expenses.
For more information, please call (215) 523-2833
- Sexual dysfunction study: The Mood Disorders Program at Thomas Jefferson University is leading a multicenter clinical trial for patients whose major depressive disorder has remitted with an antidepressant but who have antidepressant-related sexual dysfunction. Patients will be randomized to receive either vilazodone (Viibryd) or sertraline (Zoloft). No patient will receive only placebo. The study will last for up to 11 weeks. Participants will be reimbursed for their time and for travel.
- Genetic testing study: Patients who have taken or are currently taking certain antidepressant medications who EITHER
- Took the antidepressant and experienced significant side effects, OR
- Took the antidepressant, had less than a 30% reduction in depression, and had minimal side effects.
- Excessive Sweating study: Patients with clinical depression who have complaints of excessive sweating thought to be a side effect of their antidepressant may be suitable for participation in an ongoing clinical trial in which participants will have another medication added to an antidepressant to assess how well this potential drug works to treat sweating caused by antidepressants. All patients will receive the medication; no placebo is used.
For more information, please call (215) 503-2834
Depression Treatment Non-medication Study
A unique 8-week research study at Thomas Jefferson University and the Myrna Brind Center of Intergrative Medicine is evaluating a nutritional supplement that may help relieve depression symptoms. Enrolled participants will receive an initial evaluation, study nutritional supplement, and follow-up visits at no cost. For more information call
In the News
Matthew Wintersteen, Ph.D., Assistant Professor in the Department of Psychiatry and Human Behavior is the Principal Investigator of a $1.2 million subcontract for suicide prevention efforts from the Commonwealth of Pennsylvania received by Jefferson.
At the annual Benjamin Rush Ball held on November 21, 2014, the Philadelphia Psychiatric Society presented Rajnish Mago, MD, Director of the Mood Disorders Program the iPsychiatric Educator of the Year award, and nominated Blake Rosenthal, MD, Chief Resident in the Department of Psychiatry and Human Behavior for the Psychiatric Resident of the Year award.